These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 12086857)
1. Molecular mechanisms of lymphangiogenesis in health and disease. Alitalo K; Carmeliet P Cancer Cell; 2002 Apr; 1(3):219-27. PubMed ID: 12086857 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Mäkinen T; Jussila L; Veikkola T; Karpanen T; Kettunen MI; Pulkkanen KJ; Kauppinen R; Jackson DG; Kubo H; Nishikawa S; Ylä-Herttuala S; Alitalo K Nat Med; 2001 Feb; 7(2):199-205. PubMed ID: 11175851 [TBL] [Abstract][Full Text] [Related]
3. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269 [TBL] [Abstract][Full Text] [Related]
4. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889 [TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. Paavonen K; Mandelin J; Partanen T; Jussila L; Li TF; Ristimaki A; Alitalo K; Konttinen YT J Rheumatol; 2002 Jan; 29(1):39-45. PubMed ID: 11824969 [TBL] [Abstract][Full Text] [Related]
6. Molecular control of lymphatic metastasis. Achen MG; Stacker SA Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of lymphangiogenesis. Takahashi M; Yoshimoto T; Kubo H Int J Hematol; 2004 Jul; 80(1):29-34. PubMed ID: 15293565 [TBL] [Abstract][Full Text] [Related]
8. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study. Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927 [TBL] [Abstract][Full Text] [Related]
9. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Partanen TA; Paavonen K Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156 [TBL] [Abstract][Full Text] [Related]
10. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Yonemura Y; Fushida S; Bando E; Kinoshita K; Miwa K; Endo Y; Sugiyama K; Partanen T; Yamamoto H; Sasaki T Eur J Cancer; 2001 May; 37(7):918-23. PubMed ID: 11313181 [TBL] [Abstract][Full Text] [Related]
11. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Clarijs R; Schalkwijk L; Ruiter DJ; de Waal RM Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1422-8. PubMed ID: 11381041 [TBL] [Abstract][Full Text] [Related]
12. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. Saaristo A; Veikkola T; Enholm B; Hytönen M; Arola J; Pajusola K; Turunen P; Jeltsch M; Karkkainen MJ; Kerjaschki D; Bueler H; Ylä-Herttuala S; Alitalo K FASEB J; 2002 Jul; 16(9):1041-9. PubMed ID: 12087065 [TBL] [Abstract][Full Text] [Related]